会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION
    • 治疗与G-CSF给药相关的并发症和疾病的方法
    • US20140199316A1
    • 2014-07-17
    • US14163192
    • 2014-01-24
    • Robert SACKSTEIN
    • Robert SACKSTEIN
    • C07K16/40
    • C07K16/40A61K39/3955A61K2039/505
    • The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics (including aptamers) and organic compounds (e.g., glycomimetics).
    • 本实施方案涉及MPO抑制剂和MPO和E-选择蛋白结合抑制剂的新用途。 在一些实施方案中,提供了用于治疗G-CSF诱导的血管并发症和关联组织损伤的方法,包括向有需要的受试者施用抑制E-选择蛋白受体/配体相互作用或抑制MPO活性的化合物。 抑制剂可以与G-CSF治疗联合施用。 抑制剂包括抗体分子,以及同源物,类似物和其修饰或衍生形式,包括免疫球蛋白片段如Fab,F(ab')2和Fv,小分子,包括肽,寡核苷酸,肽模拟物(包括适体)和有机化合物 (例如,糖模拟物)。
    • 8. 发明申请
    • METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION
    • 治疗与G-CSF给药相关的并发症和疾病的方法
    • US20130224217A1
    • 2013-08-29
    • US13465691
    • 2012-05-07
    • Robert SACKSTEIN
    • Robert SACKSTEIN
    • A61K39/395
    • C07K16/40A61K39/3955A61K2039/505
    • The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics (including aptamers) and organic compounds (e.g., glycomimetics).
    • 本实施方案涉及MPO抑制剂和MPO和E-选择蛋白结合抑制剂的新用途。 在一些实施方案中,提供了用于治疗G-CSF诱导的血管并发症和关联组织损伤的方法,包括向有需要的受试者施用抑制E-选择蛋白受体/配体相互作用或抑制MPO活性的化合物。 抑制剂可以与G-CSF治疗联合施用。 抑制剂包括抗体分子,以及同系物,类似物及其修饰或衍生形式,包括免疫球蛋白片段如Fab,F(ab')2和Fv,小分子,包括肽,寡核苷酸,肽模拟物(包括适体)和有机化合物 (例如,糖模拟物)。